Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2M | 1M | 0 | 0 | 0 |
| Gross Profit | 334K | 294K | 0 | 0 | 0 |
| Operating Income | -1M | -3M | -845K | -231K | -13K |
| EBITDA | -899K | -3M | 0 | 0 | 0 |
| Net Income | -689K | -3M | -845K | -231K | -13K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0089
-0.78% today
1Y Change
-38.68%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xcelerate Inc. (XCRT) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.01 and down 38.7% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -75.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -75.0%, free cash flow +51.5% with operating margin -24.9% and ROIC -72.0%. Valuation sits in the middle of the pack at price/sales 6.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XCRT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XCRT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XCRT Max Drawdown
-60.31%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XCRT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$13.2K
+94.3% YoY
Free Cash Flow
-$13.2K
+90.9% YoY
Revenue Growth
-100.0%
EPS Growth
-75.0%
Gross Margin
25.1%
Net Margin
-22.8%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2M | 1M | 0 | 0 | 0 |
| Gross Profit | 334K | 294K | 0 | 0 | 0 |
| Operating Income | -1M | -3M | -845K | -231K | -13K |
| EBITDA | -899K | -3M | 0 | 0 | 0 |
| Net Income | -689K | -3M | -845K | -231K | -13K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 124K | 238K | 19K | 0 | 0 |
| Total Assets | 2M | 2M | 229K | 0 | 0 |
| Total Liabilities | 3M | 2M | 247K | 224K | 20K |
| Shareholder Equity | -835K | -166K | -18K | -224K | -20K |
| Total Debt | 2M | 1M | 132K | 165K | 20K |
| Net Debt | 2M | 1M | 113K | 165K | 20K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
13K
+90.9% YoY
Capital Expenditures
0
Free Cash Flow
13K
+90.9% YoY
Key ratios
Gross Margin
25.1%
Operating Margin
-24.9%
Net Margin
-22.8%
ROE
26.3%
Debt / Equity
-1.81x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.